Brief: Data From Adaptimmune Trial Indicate Adding Akti To Manufacturing May Contribute To Sustained Antitumor Activity Of Next-Gen Spear T-Cells

Adaptimmune Therapeutics

12/11/2021 12:34

Nov 12 (Reuters) - Adaptimmune Therapeutics PLC  ADAP.O :
    * TRANSLATIONAL DATA AT SITC 2021 FROM ADAPTIMMUNE’S PHASE 1
SURPASS TRIAL INDICATE ADDING AKTI TO MANUFACTURING MAY
CONTRIBUTE TO SUSTAINED ANTITUMOR ACTIVITY OF NEXT-GEN SPEAR
T-CELLS
    * ADAPTIMMUNE - DATA SUGGESTS ADDITION OF AKTI DURING
MANUFACTURE
CAN REMODEL GENE EXPRESSION TOWARDS BETTER PROLIFERATION OR
BETTER CYTOTOXICITY
    * ADAPTIMMUNE THERAPEUTICS - AKTI INCREASES MEDIAN
PERSISTENCE
POST-INFUSION ; IN SOME PATIENTS, SIGNIFICANTEXPANSION IMPLIED
BY HIGHER PEAK RECOVERY

Source text for Eikon:  ID:nGNXb33X3B 
Further company coverage:  ADAP.O 

 ((Reuters.Briefs@thomsonreuters.com;))